Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study (vol 17, e0271907, 2022)

被引：0
|
作者：
Wakasakii, Takahiro
Manako, Tomomi
Yasumatsui, Ryuji
Hara, Hirotaka
Toh, Satoshi
Masuda, Muneyuki
Yamauchiid, Moriyasu
Kuratomi, Yuichiro
Nishimura, Emi
Takeuchi, Toranoshin
Matsuo, Mioko
Jiromaru, Rina
Hashimoto, Kazuki
Komune, Noritaka
Nakagawa, Takashi
机构：
来源：
PLOS ONE | 2024年 / 19卷 / 05期
关键词：
D O I：
10.1371/journal.pone.0303720
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study
    Wakasaki, Takahiro
    Manako, Tomomi
    Yasumatsu, Ryuji
    Hara, Hirotaka
    Toh, Satoshi
    Masuda, Muneyuki
    Yamauchi, Moriyasu
    Kuratomi, Yuichiro
    Nishimura, Emi
    Takeuchi, Toranoshin
    Matsuo, Mioko
    Jiromaru, Rina
    Hashimoto, Kazuki
    Komune, Noritaka
    Nakagawa, Takashi
    PLOS ONE, 2022, 17 (07):
  • [2] Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Fushimi, Chihiro
    Baba, Daisuke
    Masubuchi, Tatsuo
    Yamazaki, Morio
    Kitani, Yosuke
    Kitajima, Tatsuya
    Tanaka, Junpei
    Hanyu, Kenji
    Tanaka, Naruhisa
    Miura, Kouki
    Tada, Yuichiro
    IN VIVO, 2020, 34 (05): : 2653 - 2657
  • [3] Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Suzuki, Shinsuke
    Toyoma, Satoshi
    Kawasaki, Yohei
    Koizumi, Koh
    Iikawa, Nobuko
    Shiina, Kazuhiro
    Endo, Tentaro
    Abe, Tomoe
    Kouga, Teppei
    Yamada, Takechiyo
    MEDICINA-LITHUANIA, 2021, 57 (11):
  • [4] Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
    Tanaka, Hideki
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Tanaka, Nobukazu
    Takeshita, Naohiro
    Onaga, Ryutaro
    Hoshi, Yuta
    Wada, Akihisa
    Sato, Masanobu
    Ueda, Yuri
    Tahara, Makoto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors
    Sakai, Akihiro
    Ebisumoto, Koji
    Iijima, Hiroaki
    Yamauchi, Mayu
    Teramura, Takanobu
    Yamazaki, Aritomo
    Watanabe, Takane
    Inagi, Toshihide
    Maki, Daisuke
    Okami, Kenji
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [6] Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors
    Akihiro Sakai
    Koji Ebisumoto
    Hiroaki Iijima
    Mayu Yamauchi
    Takanobu Teramura
    Aritomo Yamazaki
    Takane Watanabe
    Toshihide Inagi
    Daisuke Maki
    Kenji Okami
    Discover Oncology, 14
  • [7] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Daste, Amaury
    Martin, Nicolas
    Pons-Tostivint, Elvire
    Auperin, Anne
    Herrera-Gomez, Ruth Gabriela
    Baste-Rotllan, Neus
    Bidault, Francois
    Guigay, Joel
    Le Tourneau, Christophe
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 123 - 129
  • [8] A comparison of cetuximab-containing regimens for recurrent/metastatic squamous cell head and neck carcinoma: the clinical significance of weekly paclitaxel and cetuximab
    Nakano, K.
    Marshall, S.
    Taira, S.
    Sato, Y.
    Tomomatsu, J.
    Sasaki, T.
    Shimbashi, W.
    Fukushima, H.
    Yonekawa, H.
    Mitani, H.
    Kawabata, K.
    Takahashi, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Activity of weekly paclitaxel−cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    I. Pajares Bernad
    J. Martínez Trufero
    L. Calera Urquizu
    R. A. Pazo Cid
    A. Cebollero de Miguel
    M. J. Agustin
    M. Lanzuela
    A. Antón
    Clinical and Translational Oncology, 2017, 19 : 769 - 776
  • [10] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
12345